A Comparative Study of the CYP450 Inhibition Potential of Marketed Drugs Using Two Fluorescence Based Assay Platforms Routinely Used in the Pharmaceutical Industry

Publisher： Bentham Science Publishers

E-ISSN： 1874-0758|5|1|30-39

ISSN： 1872-3128

Source： Drug Metabolism Letters, Vol.5, Iss.1, 2011-01, pp. : 30-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characterizing early prescribers of newly marketed drugs in Canada: a population-based study

By Kozyrskyj Anita   Raymond Colette   Racher Amber  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 6, 2007-06 ,pp. : 597-604

Springer Publishing Company

Access to resources Recommend Favorite

Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

By Zhou Shufeng  

Clinical Pharmacokinetics, Vol. 44, Iss. 3, 2005-01 ,pp. : 279-304

Adis International

Access to resources Recommend Favorite

An In Vitro, High Throughput, Seven CYP Cocktail Inhibition Assay for the Evaluation of New Chemical Entities Using LC-MS/MS

By  

Drug Metabolism Letters, Vol. 5, Iss. 1, 2011-01 ,pp. : 17-24

Bentham Science Publishers

Access to resources Recommend Favorite

Prediction of drug‐drug interactions using physiologically‐based pharmacokinetic models of CYP450 modulators included in Simcyp software

By  

Biopharmaceutics And Drug Disposition, Vol. 39, Iss. 1, 2018-01 ,pp. : 3-17

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid Classification of CYP3A4 Inhibition Potential Using Support Vector Machine Approach

By  

Letters in Drug Design & Discovery, Vol. 4, Iss. 3, 2007-04 ,pp. : 192-200

Bentham Science Publishers

Access to resources Recommend Favorite